Abbott Laboratories Stock price
Equities
ABT
US0028241000
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
113.7 USD | +0.16% | +1.93% | +3.26% |
Financials (USD)
Sales 2024 * | 41.98B | Sales 2025 * | 44.97B | Capitalization | 197B |
---|---|---|---|---|---|
Net income 2024 * | 6B | Net income 2025 * | 6.94B | EV / Sales 2024 * | 4.77 x |
Net Debt 2024 * | 3.14B | Net cash position 2025 * | 1.23B | EV / Sales 2025 * | 4.36 x |
P/E ratio 2024 * |
32.9
x | P/E ratio 2025 * |
28.5
x | Employees | 114,000 |
Yield 2024 * |
1.9% | Yield 2025 * |
2.04% | Free-Float | 86.76% |
Latest transcript on Abbott Laboratories
1 day | +0.16% | ||
1 week | +1.93% | ||
Current month | -4.20% | ||
1 month | -5.32% | ||
3 months | +2.95% | ||
6 months | +15.84% | ||
Current year | +3.26% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 50 | 14-12-31 |
Philip Boudreau
DFI | Director of Finance/CFO | 51 | 96-12-31 |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 89-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Starks
BRD | Director/Board Member | 69 | 17-02-15 |
John Stratton
BRD | Director/Board Member | 63 | 17-06-28 |
Nancy McKinstry
BRD | Director/Board Member | 65 | 11-12-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.18% | 18 M€ | +6.77% | - | |
5.19% | 2 M€ | -.--% | ||
3.00% | 2 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 113.7 | +0.16% | 5,278,215 |
24-03-27 | 113.5 | +1.78% | 7,533,356 |
24-03-26 | 111.5 | +1.35% | 7,770,829 |
24-03-25 | 110 | -0.51% | 6,622,414 |
24-03-22 | 110.6 | -0.84% | 5,387,719 |
Delayed Quote Nyse, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.26% | 197B | |
+5.79% | 116B | |
+1.48% | 71.49B | |
+11.77% | 53.47B | |
+18.31% | 48.42B | |
+6.33% | 43.64B | |
+12.38% | 28.97B | |
+9.76% | 28.47B | |
+10.35% | 27.78B | |
+18.09% | 27.08B |